EPAT (Extracorporeal Pulse Activation Technology) is a noninvasive treatment that sends acoustic pressure waves through the skin into injured soft tissue to stimulate healing. It’s a form of radial shockwave therapy, used primarily for chronic musculoskeletal conditions like plantar fasciitis, Achilles tendon problems, and shoulder calcifications. A typical course involves three to five sessions spaced one week apart, with each session lasting roughly 10 to 15 minutes.
How Pressure Waves Trigger Healing
The device works by accelerating a small projectile inside the handpiece using compressed air. When the projectile strikes the applicator tip pressed against your skin, it generates a radial pressure wave that spreads outward into the tissue beneath. These waves are low to medium energy, and their intensity decreases as they travel deeper, which makes them best suited for conditions relatively close to the surface.
When those pressure waves reach damaged tissue, cells physically sense the mechanical force and convert it into biological signals. This process kicks off several changes at once: cells begin to multiply and migrate toward the injury site, new blood vessels form in tissue that previously had poor circulation, and the body ramps up production of collagen, the structural protein that tendons and ligaments are made of. The waves also appear to reduce pain by overstimulating local nerve endings and increasing the body’s own pain-inhibiting chemicals in the area.
For tendons specifically, shockwave treatment has been shown to trigger the release of multiple growth factors involved in tissue repair. The result is not just pain relief but actual structural changes in the damaged tissue, including improved blood supply and new collagen formation.
Conditions EPAT Treats
EPAT is most commonly used for chronic soft tissue injuries that haven’t responded to rest, physical therapy, or other conservative treatments. The conditions with the strongest evidence include:
- Plantar fasciitis, the most widely studied indication
- Achilles tendinopathy
- Calcific tendinitis of the shoulder
- Lateral epicondylitis (tennis elbow)
- Medial tibial stress syndrome (shin splints)
- Trigger points in chronically tight muscles
The word “chronic” matters here. EPAT works by restarting a healing response in tissue where the body’s natural repair process has stalled. For acute injuries that are still in the early inflammatory phase, the treatment is generally unnecessary and could be counterproductive.
What the Success Rates Look Like
Plantar fasciitis is where the data is clearest. In a retrospective study of patients treated with radial shockwave therapy, success rates climbed over time: 19% felt significant improvement at one month, 70% at three months, and 98% at one year. Pain scores dropped by about 48% one month after the final session, 68% at three months, and 86% at one year. The recurrence rate at one year was just 8%.
That timeline is important to understand. EPAT doesn’t provide instant relief for most people. The pressure waves set biological processes in motion, and those processes take weeks to months to fully play out. Many patients notice meaningful improvement between the second and third month after completing treatment.
Radial vs. Focused Shockwave Therapy
EPAT is specifically a radial pressure wave device, which is one of two main types of shockwave therapy. The distinction matters because the two types behave differently in tissue.
Focused shockwave therapy generates waves inside the device and uses a lens to concentrate them at a specific depth, delivering high energy to a precise point. Radial pressure waves, like those from EPAT, spread outward from the applicator tip and lose energy as they penetrate deeper. This makes radial therapy better for broader, superficial conditions (like plantar fasciitis or tennis elbow) and focused therapy better for deeper structures or calcifications that need high-energy targeting. Clinically, both types have good evidence for overlapping conditions, and some practitioners use them in combination.
What a Session Feels Like
During treatment, a gel is applied to your skin and the handheld applicator is pressed against the treatment area. You’ll feel a rapid tapping or pulsing sensation as the device delivers several thousand pulses over the course of the session. The treatment is uncomfortable, sometimes significantly so, depending on the energy level used and how sensitive the area is. Most providers adjust the intensity based on your tolerance.
The most common side effects are redness, mild bruising, and soreness at the treatment site. At higher energy levels, tiny pinpoint bleeding spots can appear on the skin. Some patients feel lightheaded during treatment due to the pain intensity triggering a drop in blood pressure. No serious complications are expected when the treatment is performed according to standard protocols. There’s typically no downtime afterward, though you may be sore for a day or two.
Who Should Avoid EPAT
The contraindications are relatively narrow. People with severe blood clotting disorders should not receive high-energy shockwave therapy due to the risk of bleeding in the tissue. The treatment should never be directed at areas near the lungs, as acoustic waves can cause lung tissue tears or a collapsed lung. Pregnant individuals should not receive treatment near the uterus. Active severe infections in the treatment area are also a contraindication.
Cost and Insurance Coverage
EPAT sessions typically cost between $200 and $500 each, meaning a full course of three to five treatments runs roughly $600 to $2,500. Most insurance plans consider EPAT an elective procedure, so coverage is inconsistent. Some plans cover shockwave therapy for specific FDA-cleared indications, while others exclude it entirely. It’s worth checking with your insurer before scheduling, as out-of-pocket costs add up quickly across multiple sessions.
The FDA has classified extracorporeal shockwave devices as class II medical devices, with specific clearance for conditions like chronic wounds. Many of the musculoskeletal applications, while well-supported by clinical evidence, fall outside the narrow scope of official FDA clearance, which is part of why insurance coverage remains limited.